Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer.

ABSTRACT:

Importance

The 2017 international PACIFIC trial established a role for immunotherapy after chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC). However, in the US, patients with NSCLC commonly differ from clinical trial populations in terms of age, health, access to care, and treatment course, which may all factor into the efficacy of immunotherapy.

Objective

To determine the outcomes of immunotherapy use in unresectable stage III NSCLC in the general US population.

Design, setting, and participants

This cohort study analyzed the National Cancer Database for patients diagnosed with clinical stage III NSCLC between 2015 and 2017 with follow-up through the end of 2018 who were treated with chemotherapy and radiation. Data were analyzed January 2

SUBMITTER: Pichert MD 

PROVIDER: S-EPMC9353596 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature